Cethromycin

Cethromycin

Clinical data
Routes of administration	Oral
Legal status
Legal status	Phase III Clinical Trials in US
Identifiers
IUPAC name (1S, 2R, 5R, 7R, 8R, 9S, 11R, 13R, 14R) -8- [(2S, 3R, 4S, 6R) -4- Dimethylamino -3- hydroxy -6- methyloxan -2-yl] oxy-2-ethyl-1, 5, 7, 9, 11, 13-hexamethyl -9- [(E) -3- quinolin -3- ylprop -2- enoxy] -3, 17-dioxa -15-azabicyclo [12.3.0]heptadecane -4, 6, 12, 16-tetrone
CAS Number	205110-48-1
PubChem CID	5282045
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C42H59N3O10
Molar mass	765.931 g/mol

WikiDoc Resources for Cethromycin
Articles
Most recent articles on Cethromycin Most cited articles on Cethromycin Review articles on Cethromycin Articles on Cethromycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cethromycin Images of Cethromycin Photos of Cethromycin Podcasts & MP3s on Cethromycin Videos on Cethromycin
Evidence Based Medicine
Cochrane Collaboration on Cethromycin Bandolier on Cethromycin TRIP on Cethromycin
Clinical Trials
Ongoing Trials on Cethromycin at Clinical Trials.gov Trial results on Cethromycin Clinical Trials on Cethromycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cethromycin NICE Guidance on Cethromycin NHS PRODIGY Guidance FDA on Cethromycin CDC on Cethromycin
Books
Books on Cethromycin
News
Cethromycin in the news Be alerted to news on Cethromycin News trends on Cethromycin
Commentary
Blogs on Cethromycin
Definitions
Definitions of Cethromycin
Patient Resources / Community
Patient resources on Cethromycin Discussion groups on Cethromycin Patient Handouts on Cethromycin Directions to Hospitals Treating Cethromycin Risk calculators and risk factors for Cethromycin
Healthcare Provider Resources
Symptoms of Cethromycin Causes & Risk Factors for Cethromycin Diagnostic studies for Cethromycin Treatment of Cethromycin
Continuing Medical Education (CME)
CME Programs on Cethromycin
International
Cethromycin en Espanol Cethromycin en Francais
Business
Cethromycin in the Marketplace Patents on Cethromycin
Experimental / Informatics
List of terms related to Cethromycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cethromycin (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for cethromycin to treat mild-to-moderate community acquired pneumonia.